A pertinent insight from the horse's mouth worth revisiting on the subject of TGA approval of SmrtGraft (CelGro Tendon); Andrew Kohler interview - Aug 2024 - where Paul was weirdly forthcoming on a number of things the company was not in official release:
"Q: After nerves then tendons, is that the idea?"
"Out of the same platform also our third product is for the repair of tendon, ruptured tendons or torn tendons in the body. We have submitted that now to the TGA and so we're expecting to have that approved by the end of this year or early next year. That would give us our third product from the platform and further expand our commercial opportunities leveraging up the manufacturing processes that we have in Australia and our knowledge in the marketplace. Another big unmet clinical need is in the area particularly in shoulder repair and Achilles tendon repair." (my embolden)
This announcement well overdue by typical TGA timelines and company expectations.
OCC Price at posting:
$1.22 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)